EGFR and non-small cell lung carcinoma: Haratani [43] found that T790M-negative patients with EGFR mutation-positive NSCLC are more likely to benefit from Nivolumab (anti-human PD-1 monoclonal antibodies) after EGFR-TKI treatment, possibly as a result of a higher PD-L1 expression level, when compared with T790M-positive patients, which indicates that patients with other resistance mechanisms, such as MET activation, may have higher response rates compared with those with T790M mutations in NSCLC.